Alexander Kristen L.'s Insider Trades & SAST Disclosures
Alexander Kristen L.'s most recent trade in Lexicon Pharmaceuticals Inc was a trade of 19,887 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Alexander Kristen L..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 19,887 | 39,773 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 19,887 | 94,230 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 17,862 | 76,368 (0%) | 0% | 0.7 | 11,968 | Common Stock |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 15,926 | 74,343 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 15,926 | 15,927 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 10,617 | 58,417 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 10,617 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 185,540 | 185,540 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 185,540 | 185,540 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alexander L. Kristen | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 15,927 | 59,593 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alexander Kristen L. | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 15,927 | 31,853 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alexander L. Kristen | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 11,793 | 47,800 (0%) | 0% | 2.6 | 30,898 | Common Stock |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 10,616 | 10,617 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 10,616 | 43,666 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen Alexander L. | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,700 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen Alexander L. | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,700 | 33,050 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 59,660 | 59,660 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Alexander L. Kristen | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 59,660 | 59,660 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 10,617 | 21,233 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 10,617 | 35,680 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,400 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,400 | 22,363 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 5,330 | 30,350 (0%) | 0% | 2.2 | 11,566 | Common Stock |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 2,700 | 2,700 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 2,700 | 25,063 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 71,670 | 71,670 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 47,780 | 47,780 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,400 | 5,400 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,400 | 17,600 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 3,337 | 16,963 (0%) | 0% | 2.8 | 9,510 | Common Stock |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,200 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,200 | 12,200 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,700 | 20,300 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,700 | 5,400 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 47,780 | 47,780 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 31,850 | 31,850 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges